Page last updated: 2024-08-17

androstenedione and Forestier-Certonciny Syndrome

androstenedione has been researched along with Forestier-Certonciny Syndrome in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Craviotto, C; Cutolo, M; Foppiani, L; Pizzorni, C; Prete, C; Salvarani, C; Seriolo, B; Straub, RH; Sulli, A	1
Delmas, PD; Pearce, G; Ryan, PF; Seeman, E; Tabensky, DA	1
Cutolo, M; Georgi, J; Glück, T; Helmke, K; Lang, B; Schölmerich, J; Straub, RH; Vaith, P	1

Trials

1 trial(s) available for androstenedione and Forestier-Certonciny Syndrome

Article	Year
The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. British journal of rheumatology, 1998, Volume: 37, Issue:3 Topics: Aged; Alkaline Phosphatase; Androstenedione; Anti-Inflammatory Agents; Bone and Bones; Bone Density; Dehydroepiandrosterone Sulfate; Dose-Response Relationship, Drug; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Osteocalcin; Osteoporosis; Osteoporosis, Postmenopausal; Polymyalgia Rheumatica; Prednisolone; Prospective Studies	1998

Article

Year

The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica.

British journal of rheumatology, 1998, Volume: 37, Issue:3

Topics: Aged; Alkaline Phosphatase; Androstenedione; Anti-Inflammatory Agents; Bone and Bones; Bone Density; Dehydroepiandrosterone Sulfate; Dose-Response Relationship, Drug; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Osteocalcin; Osteoporosis; Osteoporosis, Postmenopausal; Polymyalgia Rheumatica; Prednisolone; Prospective Studies

1998

Other Studies

2 other study(ies) available for androstenedione and Forestier-Certonciny Syndrome

Article	Year
Cortisol, dehydroepiandrosterone sulfate, and androstenedione levels in patients with polymyalgia rheumatica during twelve months of glucocorticoid therapy. Annals of the New York Academy of Sciences, 2002, Volume: 966 Topics: Adrenal Cortex; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Aged; Aging; Androstenedione; Area Under Curve; Biomarkers; Blood Sedimentation; C-Reactive Protein; Corticotropin-Releasing Hormone; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Inflammation; Interleukin-6; Male; Neuroimmunomodulation; Pituitary-Adrenal System; Polymyalgia Rheumatica; Secretory Rate; Testis	2002
The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford, England), 2000, Volume: 39, Issue:6 Topics: Adrenal Glands; Aged; Androstenedione; Dehydroepiandrosterone; Hormones; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Interleukin-6; Male; Middle Aged; Pituitary-Adrenal System; Polymyalgia Rheumatica; Tumor Necrosis Factor-alpha	2000

Article

Year

Cortisol, dehydroepiandrosterone sulfate, and androstenedione levels in patients with polymyalgia rheumatica during twelve months of glucocorticoid therapy.

Annals of the New York Academy of Sciences, 2002, Volume: 966

Topics: Adrenal Cortex; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Aged; Aging; Androstenedione; Area Under Curve; Biomarkers; Blood Sedimentation; C-Reactive Protein; Corticotropin-Releasing Hormone; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Inflammation; Interleukin-6; Male; Neuroimmunomodulation; Pituitary-Adrenal System; Polymyalgia Rheumatica; Secretory Rate; Testis

2002

The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica.

Rheumatology (Oxford, England), 2000, Volume: 39, Issue:6

Topics: Adrenal Glands; Aged; Androstenedione; Dehydroepiandrosterone; Hormones; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Interleukin-6; Male; Middle Aged; Pituitary-Adrenal System; Polymyalgia Rheumatica; Tumor Necrosis Factor-alpha

2000